Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan.

Gray JE, Heist RS, Starodub AN, Camidge DR, Kio EA, Masters GA, Purcell WT, Guarino MJ, Misleh J, Schneider CJ, Schneider BJ, Ocean A, Johnson T, Gandhi L, Kalinsky K, Scheff R, Messersmith WA, Govindan SV, Maliakal PP, Mudenda B, Wegener WA, Sharkey RM, Goldenberg DM.

Clin Cancer Res. 2017 Oct 1;23(19):5711-5719. doi: 10.1158/1078-0432.CCR-17-0933. Epub 2017 Jul 5.

2.

Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.

Ocean AJ, Starodub AN, Bardia A, Vahdat LT, Isakoff SJ, Guarino M, Messersmith WA, Picozzi VJ, Mayer IA, Wegener WA, Maliakal P, Govindan SV, Sharkey RM, Goldenberg DM.

Cancer. 2017 Oct 1;123(19):3843-3854. doi: 10.1002/cncr.30789. Epub 2017 May 30.

3.

Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.

Heist RS, Guarino MJ, Masters G, Purcell WT, Starodub AN, Horn L, Scheff RJ, Bardia A, Messersmith WA, Berlin J, Ocean AJ, Govindan SV, Maliakal P, Mudenda B, Wegener WA, Sharkey RM, Goldenberg DM, Camidge DR.

J Clin Oncol. 2017 Aug 20;35(24):2790-2797. doi: 10.1200/JCO.2016.72.1894. Epub 2017 May 26.

PMID:
28548889
4.

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O'Shaughnessy J, Kalinsky K, Guarino M, Abramson V, Juric D, Tolaney SM, Berlin J, Messersmith WA, Ocean AJ, Wegener WA, Maliakal P, Sharkey RM, Govindan SV, Goldenberg DM, Vahdat LT.

J Clin Oncol. 2017 Jul 1;35(19):2141-2148. doi: 10.1200/JCO.2016.70.8297. Epub 2017 Mar 14.

5.

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.

Starodub AN, Ocean AJ, Shah MA, Guarino MJ, Picozzi VJ Jr, Vahdat LT, Thomas SS, Govindan SV, Maliakal PP, Wegener WA, Hamburger SA, Sharkey RM, Goldenberg DM.

Clin Cancer Res. 2015 Sep 1;21(17):3870-8. doi: 10.1158/1078-0432.CCR-14-3321. Epub 2015 May 5.

6.

Single centre prospective study of the efficacy of percutaneous cement augmentation in the treatment of vertebral compression fractures.

Joseph RN, Swift AJ, Maliakal PJ.

Br J Neurosurg. 2013 Aug;27(4):459-64. doi: 10.3109/02688697.2012.752431. Epub 2012 Dec 29.

PMID:
24350763
7.

Factors that affect the efficacy of fluoroscopically guided selective spinal nerve root block in the treatment of radicular pain: a prospective cohort study.

Mallinson PI, Tapping CR, Bartlett R, Maliakal P.

Can Assoc Radiol J. 2013 Nov;64(4):370-5. doi: 10.1016/j.carj.2013.03.001. Epub 2013 Aug 12.

8.

Anticancer activity of tolfenamic acid in medulloblastoma: a preclinical study.

Eslin D, Lee C, Sankpal UT, Maliakal P, Sutphin RM, Abraham L, Basha R.

Tumour Biol. 2013 Oct;34(5):2781-9. doi: 10.1007/s13277-013-0836-6. Epub 2013 May 18.

PMID:
23686785
9.

Tolfenamic acid suppresses cytochrome P450 2E1 expression in mouse liver.

Shukoor MI, Tiwari S, Sankpal UT, Maliakal P, Connelly SF, Siddiqi S, Siddiqi SA, Basha R.

Integr Biol (Camb). 2012 Sep;4(9):1122-9. doi: 10.1039/c2ib20127e. Epub 2012 Jul 26.

10.

Expression of specificity protein transcription factors in pancreatic cancer and their association in prognosis and therapy.

Sankpal UT, Maliakal P, Bose D, Kayaleh O, Buchholz D, Basha R.

Curr Med Chem. 2012;19(22):3779-86. Review.

PMID:
22725697
11.

Environmental factors in causing human cancers: emphasis on tumorigenesis.

Sankpal UT, Pius H, Khan M, Shukoor MI, Maliakal P, Lee CM, Abdelrahim M, Connelly SF, Basha R.

Tumour Biol. 2012 Oct;33(5):1265-74. doi: 10.1007/s13277-012-0413-4. Epub 2012 May 22. Review.

PMID:
22614680
12.

Small molecule tolfenamic acid inhibits PC-3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer.

Sankpal UT, Abdelrahim M, Connelly SF, Lee CM, Madero-Visbal R, Colon J, Smith J, Safe S, Maliakal P, Basha R.

Prostate. 2012 Nov;72(15):1648-58. doi: 10.1002/pros.22518. Epub 2012 Apr 2.

PMID:
22473873
13.

Tolfenamic acid inhibits neuroblastoma cell proliferation and induces apoptosis: a novel therapeutic agent for neuroblastoma.

Eslin D, Sankpal UT, Lee C, Sutphin RM, Maliakal P, Currier E, Sholler G, Khan M, Basha R.

Mol Carcinog. 2013 May;52(5):377-86. doi: 10.1002/mc.21866. Epub 2011 Dec 28.

PMID:
22213339
14.

Central pontine myelinolysis without hyponatraemia.

Bose P, Kunnacherry A, Maliakal P.

J R Coll Physicians Edinb. 2011 Sep;41(3):211-4. doi: 10.4997/JRCPE.2011.305.

PMID:
21949915
15.

Relevance of drug metabolizing enzyme activity modulation by tea polyphenols in the inhibition of esophageal tumorigenesis.

Maliakal P, Sankpal UT, Basha R, Maliakal C, Ledford A, Wanwimolruk S.

Med Chem. 2011 Sep;7(5):480-7.

PMID:
21801144
16.

Evaluation of spinal dural arteriovenous fistulae with gadofosveset trisodium at 3 T (TRICKS and LAVA).

Tapping CR, Thackeray AT, Bartlett RJ, Rowland-Hill C, Maliakal P.

Clin Radiol. 2011 Sep;66(9):865-8. doi: 10.1016/j.crad.2011.02.011. Epub 2011 May 4. No abstract available.

PMID:
21546012
17.

Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in rats.

Maliakal P, Abdelrahim M, Sankpal UT, Maliakal C, Baker CH, Safe S, Herrera LJ, Abudayyeh A, Kaja S, Basha R.

Invest New Drugs. 2012 Jun;30(3):853-61. doi: 10.1007/s10637-010-9622-0. Epub 2011 Jan 4.

PMID:
21197621
18.

Electrolyte and protein imbalance following anti-EGFR therapy in cancer patients: A comparative study.

Maliakal P, Ledford A.

Exp Ther Med. 2010 Mar;1(2):307-311. Epub 2010 Mar 1.

19.

Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice.

Meng X, Maliakal P, Lu H, Lee MJ, Yang CS.

J Agric Food Chem. 2004 Feb 25;52(4):935-42.

PMID:
14969553
20.

Delivery of tea polyphenols to the oral cavity by green tea leaves and black tea extract.

Lee MJ, Lambert JD, Prabhu S, Meng X, Lu H, Maliakal P, Ho CT, Yang CS.

Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):132-7.

21.

Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability.

Lee MJ, Maliakal P, Chen L, Meng X, Bondoc FY, Prabhu S, Lambert G, Mohr S, Yang CS.

Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1025-32.

22.

Decreased hepatic drug metabolising enzyme activity in rats with nitrosamine-induced tumours.

Maliakal PP, Coville PF, Wanwimolruk S.

Drug Metabol Drug Interact. 2002;19(1):13-27.

PMID:
12222751
23.

Inhibition of carcinogenesis by tea.

Yang CS, Maliakal P, Meng X.

Annu Rev Pharmacol Toxicol. 2002;42:25-54. Review.

PMID:
11807163
24.

Effect of herbal teas on hepatic drug metabolizing enzymes in rats.

Maliakal PP, Wanwimolruk S.

J Pharm Pharmacol. 2001 Oct;53(10):1323-9.

PMID:
11697539
25.

Oral quinine pharmacokinetics and dietary salt intake.

Newton P, Simpson A, Wanwimolruk S, Maliakal P, Villegas L, Kuypers D, White NJ.

Eur J Clin Pharmacol. 2001 May;57(2):111-3.

PMID:
11417441
26.

Tea consumption modulates hepatic drug metabolizing enzymes in Wistar rats.

Maliakal PP, Coville PF, Wanwimolruk S.

J Pharm Pharmacol. 2001 Apr;53(4):569-77.

PMID:
11341376

Supplemental Content

Loading ...
Support Center